Description: The Evaluation of New Antiarrhythmic Drugs Please note: this item is printed on demand and will take extra time before it can be dispatched to you (up to 20 working days). Proceedings of the Symposium on How to Evaluate a New Antiarrhythmic Drug: The Evaluation of New Antiarrhythmic Agents for the Treatment of Ventricular Arrhythmias, held at Philadelphia, Pennsylvania, October 8-9, 1980 Author(s): J. Morganroth, E. Neil Moore, L.S. Dreifus, E.L. Michelson Format: Paperback Publisher: Springer, Netherlands Imprint: Springer ISBN-13: 9789400982727, 978-9400982727 Synopsis Thus, there are now several chronic canine myocardial infarction ventricular tachyarrhythmia models which are available for the evaluation of new antiarrhythmic drugs (Table I). The available models fulfill many, but not all of the requirements for an ideal chronic arrhythmia model (Table 11). The sustained arrhythmias initiated in these models using programmed pacing presumably have the same localized reentrant mechanism that characterizes chronic human myocardial infarction and chronic coronary 26 artery disease. However, these models are not suitable for determining whether a new drug will abolish spontaneous ly-occurring PVCs. In addition, these models are of unproven value in the study of acute spontaneously occurring sudden death; although recently initiated, provocative work may shed further light on this subject. Most importantly, the available models do seem well-suited to the evaluation of new drugs intended for use in chronic coronary artery disease patients at risk for sustained reentrant ventricular tachycardia or VF. Notably, the results of preliminary electropharmacologic studies in these canine models parallel closely those findings reported in human patients with sustained life-threatening ventricu lar tachyarrhythmias (Table Ill). Therefore, increased use of these chronic models for new antiarrhythmic drug testing is strongly recommended. TABLE II Ideal vs Available Chronic Canine - Arrhythmia Models Ideal Available 1. (a) Arrhythmia mechanism comparable to Yes patients with chronic CAD: Reentry (b) Pathophysiology similar (e. g. , atherogenic CAD) No 2. Susceptible to: (a) spontaneous PVCs No l No (b) spontaneous VT/VF (c) inducible VT/VF Yes 3.
Price: 38.28 GBP
Location: Aldershot
End Time: 2024-12-26T08:54:39.000Z
Shipping Cost: 28.59 GBP
Product Images
Item Specifics
Return postage will be paid by: Buyer
Returns Accepted: Returns Accepted
After receiving the item, your buyer should cancel the purchase within: 60 days
Return policy details:
Book Title: The Evaluation of New Antiarrhythmic Drugs
Number of Pages: 340 Pages
Language: English
Publication Name: The Evaluation of New Antiarrhythmic Drugs: Proceedings of the Symposium on How to Evaluate a New Antiarrhythmic Drug: The Evaluation of New Antiarrhythmic Agents for the Treatment of Ventricular Arrhythmias, held at Philadelphia, Pennsylvania, October 8-9, 1980
Publisher: Springer
Publication Year: 2011
Subject: Medicine
Item Height: 235 mm
Item Weight: 522 g
Type: Textbook
Author: E. Neil Moore, J. Morganroth, E.L. Michelson, L.S. Dreifus
Series: Developments in Cardiovascular Medicine
Item Width: 155 mm
Format: Paperback
